Vicuron Pharmaceuticals Appoints Senior Directors to Establish and Lead Medical Science Liaison Field Force KING OF PRUSSIA, Pa., April 6 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) today announced the appointment of Jennifer D. Copeland, M.S. and Steven P. Gelone, Pharm.D., as Senior Directors to establish and lead the company's Medical Science Liaison field force. Ms. Copeland and Dr. Gelone are building and deploying a team of professionals whose initial focus will be to lay the groundwork for the launch of the company's investigational antifungal agent, anidulafungin, by conducting physician outreach, medical education and opinion leader development. Ms. Copeland will manage the company's medical science liaisons in the Western region and Dr. Gelone will oversee the team in the Eastern region of the United States. "Together, Jennifer and Steve bring nearly 30 years of complementary anti-infective research, medical education, training and field force experience to Vicuron," said George F. Horner III, President and Chief Executive Officer of Vicuron. "Their depth of knowledge and relationships with key opinion leaders in our key target markets should enhance early adoption, acceptance and uptake of our significantly differentiated products." Prior to joining Vicuron, Dr. Gelone spent 12 years at Temple University where he had broad responsibilities in anti-infective education, clinical research and patient management. Most recently, he served as Associate Professor of Pharmacy and Assistant Professor of Medicine specializing in infectious disease. Dr. Gelone has extensive experience with anti-infective products, serving as principal investigator on more than 50 research studies and has been involved in the formulary evaluation of new antibacterial and antifungal agents. On the patient management side, Gelone served for 10 years as Director of the Antimicrobial Management Program at Temple University Hospital, where he ran a clinical service managing hospital patients on anti-infective regimens. Dr. Gelone received a Bachelor and a Doctorate degree in Pharmacy from Temple University School of Pharmacy. Ms. Copeland spent over 13 years in positions of increasing responsibility at Abbott Laboratories, most recently as Senior Manager of Medical Liaisons for the Anti-Infective Franchise. In this position, Ms. Copeland hired, trained and managed a national team and had general oversight for opinion leader cultivation and medical education for the franchise. Prior to her most recent role, Ms. Copeland served in numerous medical liaison and sales capacities at Abbott, including Medical Liaison for Gastrointestinal & Infectious Disease, Anti-Infective Respiratory Specialist, Professional Pharmaceutical Representative and Regional Field Trainer. Before joining Abbott, Ms. Copeland served as Director of Medical Affairs for the American Cancer Society's Texas Division where she managed patient service programs, professionaleducation, volunteer recruitment and training. Ms. Copeland holds a Bachelor of Science degree in Microbiology and Biology from the University of Kansas and a Masters of Science degree in Microbiology from the University of Houston. About Vicuron Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing vital medicine for seriously ill patients in North America and major countries in Europe. The company has filed a New Drug Application with the U.S. Food and Drug Administration for its lead product, anidulafungin, a novel antifungal agent. The company's other lead product, dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive infections, is in Phase III clinical trials. The company's versatile research engine integrates industry-leading expertise in functional genomics, natural products discovery, mechanism-based drug design and combinatorial and medicinal chemistry. These approaches are yieldingpromising novel and next-generation compounds, many of which are in the later stages of preclinical development. In addition, the company has research and development collaborations with leading pharmaceutical companies, such as Pfizer and Novartis. Forward-Looking Statements This news release contains forward-looking statements that predict or describe future events or trends. The matters described in these forward-looking statements are subject to known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond Vicuron's control. Vicuron faces many risks that could cause its actual performance to differ materially from the results predicted by its forward-looking statements, including the possibilities that clinical trials and the results thereof might be delayed, that the timing of the filing of any new drug application might be delayed, that subsequent clinical trials might indicate that a product candidate is unsafe or ineffective, that any filed new drug application may not be approved, that ongoing proprietary and collaborative research might not occur or yield useful results, that a third party may not be willing to license our product candidates on terms acceptable to us or at all, that competitors might develop superior substitutes for their products or market them more effectively, that a sales force may not be developed as contemplated and that one or more of its product candidates may not be commercialized successfully. The reports that Vicuron files with the U.S. Securities and Exchange Commission contain a fuller description of these and many other risks to which Vicuron is subject. Because of those risks, Vicuron's actual results, performance or achievements may differ materially from the results, performance or achievements contemplated by its forward- looking statement. The information set forth in this news release represents management's current expectations and intentions. Vicuron assumes no responsibility to issue updates to the forward-looking matters discussed in this news release. DATASOURCE: Vicuron Pharmaceuticals Inc. CONTACT: Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals Inc., +1-610-205-2312, or ; or Hala Bashir of WeissCom Partners, +1-212-204-2080, or , or E. Blair Schoeb of Burns McClellan Inc., +1-212-213-0006, or , both for Vicuron Pharmaceuticals Inc. Web site: http://www.vicuron.com/

Copyright